newsfilter
← Latest News
Business Wire·

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (NASDAQ:KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved Kezar's